It is important to note that combinatorial therapy for melanoma clinical trials with Flt3L, DEC205/NY-ESO-1 fusion protein and poly-ICLC (NCT02129075) have demonstrated immunogenicity and safety. This evidence concerns the gene FLT3LG and melanoma.